Related Experiment Video

Updated: Jun 9, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

14.9K

PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells

Zachary A Schaaf1, Shu Ning1, Amy R Leslie1

  • 1Department of Urologic Surgery, University of California Davis, Davis, California.

Cancer Research Communications
|October 23, 2024
PubMed
Abstract

Insights

Olaparib resistance in prostate cancer is linked to mitochondrial changes and PINK1 gene overexpression. Targeting these factors may improve olaparib treatment effectiveness against resistant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Olaparib, a PARP inhibitor, shows efficacy in treating various cancers, including prostate cancer.
  • Acquired resistance to olaparib is a major clinical challenge, limiting its long-term effectiveness.

Purpose of the Study:

  • To investigate the mechanisms underlying olaparib resistance in prostate cancer cells.
  • To identify key molecular factors contributing to treatment failure.

Main Methods:

  • Comparative analysis of mitochondrial function in olaparib-sensitive and olaparib-resistant prostate cancer cell lines.
  • Gene expression analysis focusing on mitochondrial dynamics and related pathways, including PINK1.

Main Results:

  • Olaparib-resistant prostate cancer cells exhibit significant alterations in mitochondrial functionality.
  • Overexpression of the PINK1 gene was observed in olaparib-resistant cells, correlating with enhanced mitochondrial activity.
  • Increased mitochondrial dynamics were a hallmark of resistant cell phenotypes.

Conclusions:

  • Mitochondrial alterations and elevated PINK1 expression are critical contributors to olaparib resistance in prostate cancer.
  • Targeting mitochondrial dynamics and the PINK1 pathway presents a promising therapeutic strategy to overcome olaparib resistance.
  • Further research into these mechanisms could lead to novel treatment approaches for advanced prostate cancer.

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.9K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

3.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K